SynthesisBMC infectious diseases2025
Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Incidence and Outcomes of Bloodstream Infections in Critically Ill Patients with COVID-19: A Nationwide Multicenter Study in South Korea.Yonsei medical journal · 2026Observational
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRisk factors for bloodstream infection in patients with COVID-19 in the intensive care unit (ICU) remain unclear. The purpose of this systematic review was to study the risk factors for BSI in patients admitted to ICUs for COVID-19.
methodsA systematic search was performed on PubMed, EMBASE, Cochrane Library, and Web of Science up to July 2024. Data were reported as combined odds ratio (OR) for categorical variables and weighted mean difference (WMD) for continuous variables.
results6914 studies were retrieved, of which 55 were included in the meta-analysis. Men (OR = 1.28, 95% CI: 1.10-1.50, P = 0.006), high SAPS II score (WMD = 6.43, 95% CI: 0.23-12.63, P = 0.042), diabetes (OR = 1.34, 95% CI: 1.04-1.73, P = 0.022), tracheal intubation (OR = 8.68, 95% CI: 4.68-16.08, P < 0.001), mechanical ventilation (OR = 22.00, 95% CI: 3.77-128.328, P < 0.001), ECMO (OR = 2.70, 95% CI: 1.17-6.26, P = 0.020), central venous cannulation (OR = 9.33, 95% CI: 3.06-28.43, P < 0.001), prolonged ICU stay (WMD = 10.37, 95% CI: 9.29-11.44, P < 0.001), methylprednisolone use (OR = 2.24, 95% CI: 1.24-4.04, P = 0.008), and the combination of methylprednisolone and Tocilizumab (OR = 4.54, 95% CI: 1.09-18.88, P = 0.037) were risk factors for ICU-BSI in COVID-19 patients.
conclusionWe identified 10 risk factors for ICU-BSI in COVID-19 patients. In future studies, these factors can be combined to establish a more comprehensive and accurate prediction model for ICU-BSI in COVID-19 patients. Targeted measures can be taken earlier to control BSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.